Combining mTOR inhibition with NAD+ supplementation reverses epigenetic field cancerization by restoring SIRT1‑mediated DNMT suppression

Dr. Leo Kofi· Mar 23, 2026

Mechanism: Rapamycin alone reduces mTORC1 but inadvertently lowers NAD+ via AMPK-PARP, inhibiting SIRT1 and causing DNMT accumulation and tumor suppressor gene hypermethylation. Readout: Readout: NAD+ supplementation restores SIRT1, reverses methylation, and further reduces tumor count beyond rapamycin monotherapy.

Hypothesis

Chronic mTOR inhibition mimics nutrient scarcity but inadvertently lowers cellular NAD+ levels through AMPK‑driven PARP activation, which diminishes SIRT1 deacetylase activity and permits unchecked DNMT‑mediated promoter methylation of tumor‑suppressor genes in the intestinal field. Concurrent NAD+ repletion rescues SIRT1 function, attenuates methylation drift, and synergizes with rapamycin to reduce both tumor burden and field cancerization.

Mechanistic Rationale

mTORC1 suppression by rapamycin raises the AMP/ATP ratio, activating AMPK.
Active AMPK stimulates NAD+‑consuming PARP1 in response to mild mitochondrial stress, decreasing the NAD+/NADH ratio.
Reduced NAD+ limits SIRT1 activity; SIRT1 normally deacetylates and destabilizes DNMT1 and DNMT3B, keeping their expression low.
When SIRT1 is inhibited, DNMTs accumulate, leading to hypermethylation of CpG islands in tumor‑suppressor promoters (e.g., SFRP2, TFPI2) across the histologically normal mucosa.
NAD+ supplementation (e.g., nicotinamide riboside) restores the NAD+ pool, reactivates SIRT1, promotes DNMT turnover, and reverses methylation marks without altering rapamycin’s cytostatic effects.

Testable Predictions

In APC^Min/+ mice, rapamycin alone will reduce adenoma number but increase average methylation percentage of SFRP2 and TFPI2 in normal‑appearing colonic crypts compared with untreated controls.
Co‑administration of nicotinamide riboside with rapamycin will prevent the rapamycin‑induced rise in methylation and further lower adenoma count relative to rapamycin monotherapy.
Mechanistically, colonic tissue from the combination group will show higher SIRT1 activity, lower acetylated DNMT1, and reduced PARP1 activation than rapamycin‑only tissue.

Experimental Design

Animal model: APC^Min/+ mice, 6 weeks old, randomized into four groups (n=15 per group): vehicle, rapamycin (4 mg/kg chow), nicotinamide riboside (400 mg/kg chow), and combination.
Duration: 12 weeks treatment.
Endpoints:
- Tumor count and size (gross microscopy).
- Methylation analysis of SFRP2 and TFPI2 promoters in colonic mucosa 0–2 cm distal to tumors (bisulfite sequencing).
- SIRT1 activity (fluorometric deacetylase assay) and DNMT1 acetylation (Western blot with acetyl‑lysine antibody).
- PARP1 activation (PAR immunoblot) and NAD+ levels (enzymatic cycling assay).
Statistical plan: One‑way ANOVA with Tukey post‑hoc for multiple comparisons; methylation data log‑transformed prior to analysis.

Falsifiability

If rapamycin does not increase methylation of SFRP2/TFPI2 in normal mucosa, or if NAD+ supplementation fails to attenuate this methylation and does not improve tumor outcomes beyond rapamycin alone, the hypothesis is refuted. Conversely, observing the predicted molecular and phenotypic changes supports the model that mTOR‑induced NAD+ depletion drives epigenetic field cancerization and that NAD+ repletion restores epigenome integrity.